ClinicalTrials.gg
CompletedNCT02515864Updated Sep 8, 2017

Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)

A Phase 2 interventional study of FYU-981 and Placebo in Healthy, sponsored by Fuji Yakuhin Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-08.

Sponsored by Fuji Yakuhin Co., Ltd. · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

A Placebo-controlled, Four Way Crossover Study to Investigate the Effect on QT/QTc Interval of a Single Dose of FYU-981, Compared with Placebo, Using Moxifloxacin as a Positive Control, in Healthy Male and Female Volunteers.

02

Conditions studied

  • Healthy

Keywords

  • Male and Female Volunteers
03

In context

Lead sponsor

Fuji Yakuhin Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese adult subjects
  • : >=18.5 and \<27.5

Exclusion criteria

Exclusion Criteria:

  • Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    FYU-981 anticipated therapeutic dose

    Drug: FYU-981, FYU-981 Placebo, Moxifloxacin Placebo (Oral)

    Drug: FYU-981 · Drug: Placebo · Drug: Moxifloxacin Placebo

  • Experimental
    FYU-981 supratherapeutic dose

    Drug: FYU-981, Moxifloxacin Placebo (Oral)

    Drug: FYU-981 · Drug: Moxifloxacin Placebo

  • Placebo comparator
    Placebo

    Drug: FYU-981 Placebo, Moxifloxacin Placebo (Oral)

    Drug: Placebo · Drug: Moxifloxacin Placebo

  • Active comparator
    Moxifloxacin

    Drug: Moxifloxacin, FYU-981 Placebo (Oral)

    Drug: Placebo · Drug: Moxifloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. QT/QTc Interval

    Time frame: 24 hours

07

Study locations

1 site
  • Japan, Kanagawa, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Mar 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2015
First posted
Aug 5, 2015
Start
Aug 2015
Primary completionActual
Mar 2016
CompletionActual
Nov 2016
Last update
Sep 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02515864
Lead sponsor
Fuji Yakuhin Co., Ltd.
Responsible party
Sponsor
First posted
Aug 5, 2015
Start date
Aug 2015
Primary completion
Mar 2016
Completion
Nov 2016
Last update
Sep 8, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dotinurad

Start the discussion